Scalability And Reproducibility Of The AAV9 Capture Step Using KRM™ Chromatography System

Advancing cell and gene therapies (GT) beyond rare diseases and tackling the complexities of fragile viral vectors demands more than just scaling up existing manufacturing facilities—it calls for innovative approaches tailored to the unique challenges of these therapies. Viral vector manufacturing, particularly for advanced therapy medicinal products (ATMPs) like adeno-associated virus (AAV), requires low shear stress and minimal residence times, which makes traditional platform methods insufficient for reliable scale-up. To meet these demands, advanced technologies must deliver the robustness and consistency needed to unlock the full potential of gene therapies.

Chromatography technologies are central to improving downstream productivity, which is why Repligen developed its single-use (SU) KRM™ Chromatography System platform specifically for ATMPs. This system enhances process efficiency and yield, safeguards potency and product integrity, minimizes deviation risks through thoughtful design, and improves the overall user experience.

If you're working in gene therapy manufacturing and looking to overcome scale-up challenges while maximizing product quality and efficiency, explore how Repligen’s SU KRM™ Chromatography System can transform your process.